Skip to main content

Generics

  • Q&A: Genetic profiling with Dr. Anita Goel of Nanobiosym

    A new and possibly transformative technology for rapidly diagnosing and evaluating patients based on their specific genetic profile may soon begin appearing at retail pharmacies and clinics, giving pharmacists and clinicians another tool for advancing patient health outcomes and their own practice capabilities.

    Dr. Anita Goel, M.D., Ph.D.

  • Bi-Lo, Winn-Dixie add medication synchronization service

    GREENVILLE, S.C. — Bi-Lo on Thursday announced that all in-store pharmacies now offer “Refill Sync,” a free service that synchronizes customers’ maintenance medication prescriptions so that all scripts — regardless of refill dates — can be filled at the same time.

  • GAO: Federal upper limits 1.4% lower than National Average Drug Acquisition Cost

    WASHINGTON — In a report publicly released Thursday by the U.S. Government Accountability Office, the GAO found that the total draft federal upper limits amount based on the new formula under the Patient Protection and Affordable Care Act was about 1.4% lower than the total National Average Drug Acquisition Cost amount in aggregate for 1,035 outpatient drugs subject to the FUL in first quarter 2013.

  • Q&A: Taking the pulse with Mitch Rothschild of Vitals

    Selecting a doctor can be a frustrating process filled with too many unknowns, especially in today’s evolving landscape. Looking to help patients take the guesswork out of finding the ideal doctor, Vitals has developed online tools at Vitals.com to give patients visibility into quality, cost and availability.

  • Deal complete, McKesson owns more than 75% of Celesio

    SAN FRANCISCO — McKesson on Thursday confirmed that it has completed the previously announced agreement with Franz Haniel & Cie. GmbH to acquire their entire holding of Celesio shares. McKesson also confirmed it has completed the previously announced agreement with an affiliate of Elliott Management to acquire Celesio convertible bonds.  

    McKesson now exceeds 75% ownership of Celesio shares on a fully diluted basis.

  • GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs

    WASHINGTON — The Food and Drug Administration’s proposed rule on prescription drug labeling would add $4 billion annually to the nation’s healthcare costs, undercutting the cost savings that generic medicines have brought to America’s patients and healthcare system, according to an analysis released Wednesday by economic consulting firm Matrix Global Advisors.

  • Sandoz launches generic Hectorol

    PRINCETON, N.J. — Sandoz announced the launch of doxercalciferol injection vials, the first generic version of Genzyme’s Hectorol. Doxercalciferol injection vials are used for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

    “Sandoz is pleased to be the first company to market a high quality, affordable generic version of this important product to dialysis patients in the US,” Peter Goldschmidt, President of Sandoz, said.  

  • Coalition of healthcare industry stakeholders address best practices regarding controlled substances

    MOUNT PROSPECT, Ill. — The National Association of Boards of Pharmacy, along with a coalition of healthcare industry stakeholders, on Wednesday issued a consensus statement regarding the collaborative steps that will be taken to help ensure the delivery of responsible and effective patient care as it relates to the prescribing and dispensing of controlled substances. 

X
This ad will auto-close in 10 seconds